XML 44 R35.htm IDEA: XBRL DOCUMENT v3.23.2
GOODWILL AND INTANGIBLE ASSETS (Tables)
 6 Months Ended
Jun. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Goodwill
A reconciliation of changes in the Company’s goodwill by reportable segment were as follows:

(in millions)Technologies & EquipmentConsumablesConnected Technology SolutionsEssential Dental SolutionsOrthodontic and Implant SolutionsWellspect HealthcareTotal
Balance at December 31, 2022
Goodwill$5,902 $866 $— $— $— $— $6,768 
Accumulated impairment losses(4,080)— — — — — (4,080)
Goodwill, net December 31, 2022$1,822 $866 $— $— $— $— $2,688 
Translation9 4 — — — — 13 
Balance at March 31, 2023
Goodwill$5,911 $870 $— $— $— $— $6,781 
Accumulated impairment losses(4,080)— — — — — (4,080)
Goodwill, net March 31, 2023$1,831 $870 $— $— $— $— $2,701 
Realignment of goodwill$(1,831)$(870)$293 $835 $1,303 $270 $— 
Translation— — — 1 (5)6 2 
Goodwill, net June 30, 2023$— $— $293 $— $836 $— $1,298 $— $276 $— $2,703 
Schedule of Definite-lived and Indefinite-lived Intangible Assets
Identifiable definite-lived and indefinite-lived intangible assets were as follows:
June 30, 2023December 31, 2022
(in millions)Gross
Carrying
Amount		Accumulated
Amortization		Net
Carrying
Amount		Gross
Carrying
Amount		Accumulated
Amortization		Net
Carrying
Amount
Developed technology and patents$1,682 $(929)$753 $1,658 $(848)$810 
Tradenames and trademarks271 (97)174 273 (96)177 
Licensing agreements30 (26)4 30 (26)4 
Customer relationships1,059 (638)421 1,057 (600)457 
Total definite-lived$3,042 $(1,690)$1,352 $3,018 $(1,570)$1,448 
Indefinite-lived tradenames and trademarks$451 $— $451 $450 $— $450 
In-process R&D (a)
5 — 5 5 — 5 
Total indefinite-lived$456 $— $456 $455 $— $455 
Total identifiable intangible assets$3,498 $(1,690)$1,808 $3,473 $(1,570)$1,903 
(a) Intangible assets acquired in a business combination that are in-process and used in research and development ("R&D") activities are considered indefinite-lived until the completion or abandonment of the R&D efforts. The useful life and amortization of those assets will be determined once the R&D efforts are completed.